Jeremy G. Perkins
Experienced in Hemolytic Transfusion Reaction

Dr. Jeremy G. Perkins

Hematology Oncology
Walter Reed National Military Ctr, 8901 Wisconsin Ave - America Building, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Hemolytic Transfusion Reaction
Walter Reed National Military Ctr, 8901 Wisconsin Ave - America Building, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeremy Perkins is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Perkins is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Dysfibrinogenemia, Factor 11 Deficiency, Hemolytic Transfusion Reaction, and Breast Cancer.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Hemolytic Transfusion Reaction.

Specialties
Hematology Oncology
Licenses
Internal Medicine in DC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Walter Reed National Military Ctr, 8901 Wisconsin Ave - America Building, Bethesda, MD 20889

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Procedure
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 8 Less Clinical Trials

19 Total Publications

Penile diffuse large B-cell lymphoma in a young man.
Penile diffuse large B-cell lymphoma in a young man.
Journal: BMJ case reports
Published: March 14, 2025
Similar Doctors
Experienced in Hemolytic Transfusion Reaction
Dr. Susan F. Leitman
Hematology Oncology
Experienced in Hemolytic Transfusion Reaction
Dr. Susan F. Leitman
Hematology Oncology
National Institutes Of Health Clinical Ctr, Building 10, Room 1n-243, 
Bethesda, MD 
 (0.6 miles away)
301-594-1193
Languages Spoken:
English

Susan Leitman is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Leitman is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Hemochromatosis, Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, and Bone Marrow Transplant.

Experienced in Hemolytic Transfusion Reaction
Dr. Aarthi G. Shenoy
Hematology Oncology | Hematology | Oncology
Experienced in Hemolytic Transfusion Reaction
Dr. Aarthi G. Shenoy
Hematology Oncology | Hematology | Oncology

Whc Physician Group LLC

110 Irving St Nw, 
Washington, DC 
 (6.5 miles away)
202-877-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aarthi Shenoy is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Shenoy is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Non-Hodgkin Lymphoma, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration.

Experienced in Hemolytic Transfusion Reaction
Dr. Anita V. Aggarwal
Hematology Oncology | Hematology | Oncology
Experienced in Hemolytic Transfusion Reaction
Dr. Anita V. Aggarwal
Hematology Oncology | Hematology | Oncology
110 Irving St Nw, Suite 2a38, 
Washington, DC 
 (6.5 miles away)
202-865-3290
Languages Spoken:
English
See accepted insurances

Anita Aggarwal is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Aggarwal is rated as an Advanced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Breast Cancer in Men, Splenic Neoplasm, Marginal Zone Lymphoma (MZL), Breast Cancer, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Perkins's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile